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To determine whether there was a speciﬁc inﬂammatory process in severe asthmatics, the phenotypic characteristics of induced
sputum immune cells were analysed among patients with severe asthma. Twenty-two induced sputa (10 severe asthmatics) were
studied. Flow cytometric analysis was performed using immune cells of the sputum and monoclonal antibodies to CD3, CD4,
CD8, CD56, CD25, and TCRγδ. The number of NKT (CD3+CD56+) cells was signiﬁcantly higher in the sputum of severe asth-
matics compared with mild asthmatic and healthy control groups (P<. 05). CD8+CD56+ cells were the predominant subtype of
the increased NKT cells in severe asthmatics. CD3+CD56+Vα24+,T C R γδ+ CD56+, and CD4+CD25+ T cells were signiﬁcantly in-
creased in severe asthmatic patients. These results suggest that the immunopathogenesis of severe asthmatics vary between severe
and mild asthmatics, and that CD8+CD56+ NKT cells may play an important role in the immunopathogenesis of severe asthma.
Copyright © 2006 Agnes Hamzaoui et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Asthma is recognized by the presence of reversible bron-
choconstriction, airway hyperresponsiveness, and airway in-
ﬂammation [1]. These clinical features result from a chronic
inﬂammation of the airways, caused by a migration of leu-
cocytes and an increase of inﬂammatory mediators in the
bronchial wall [2]. This pathological reaction in asthma is
thought to arise from a complex interaction between genes
and the environment. Diﬀerent immunopathogenic mecha-
nisms and immune cells may be involved in the development
of asthma [3], natural killer T (NKT) cells constitute one of
the regulatory cells not well deﬁned in asthma.
Natural killer T (NKT) cells are heterogeneous T-cell
populations that are characterised by the coexpression of
TCRs and various NK receptors, including CD16, CD56,
CD161, CD94, CD158a, and CD158b [4]. NKT cells have
been considered to regulate autoimmunity and adaptive im-
mune responses [4–6], even though the pleiotropic nature
of NKT cells creates some controversy regarding their func-
tional role at diﬀerent inﬂammatory sites [7–10]. Distur-
bances in the numbers and functions of the NKT cells have
been implicated in several organ-speciﬁc animal models of
a u t o i m m u n i tya sw e l la si nh u m a n s[ 11, 12]. The proportion
of NKT cells among the induced sputum cells in the severe
asthmatic patients has not yet been studied.
Therefore, in this study we asked whether there are phe-
notypic diﬀerencesin the sputumimmune celltypes, includ-
ing the NKT cells, in patients with severe asthma and in pa-
tients with mild asthma. The subtypes of CD56+ T cells, in-
cluding γδ T cells, Vα24+ T cells, and CD8+CD56+ T cells,
were analysed.
PATIENTS AND METHODS
Patients
Induced sputum samples were collected from 22 successive
patientswithasthma(10patientsinsevereasthma)(Table 1).
Allwereoutpatientsinsteadystate,regulatoryfollowedbyan
asthmaspecialist.Theseverityofthediseasewasclassiﬁedac-
cording to GINA recommendations [13]. The samples were
obtained on the day of the ﬁxed visit. A precise history of the
patient was previously obtained with functional respiratory
tests. The following patients were excluded: acute exacerba-
tion of asthma, concomitant respiratory infection, other pul-
monary diseases, and smokers.
Ten induced sputum from healthy subjects—females
with a mean age of 28.7 years (range 18–39 years), who had
normal pulmonary radiographs and showed no clinical signs
of respiratory diseases—acted as controls. Informed consent
was obtained from all the patients. The study was approved
by our Ethics Committee.2 Mediators of Inﬂammation
Table 1: Cellular characteristics of induced sputum. Diﬀerential sputum cell counts are expressed as percentage of nonsquamous cells.
Healthy controls Severe asthmatics Mild asthmatics
Number/Sex (F) 10 (F) 10 (F) 12 (F)
Age 28.7 ±6.24 8 .6 ±3.55 5 .2 ±3.2
FEV1 (% predicted) 93.2 ±4.85 8 .7 ±6.2† 87.3 ±2.5
T o t a lc e l lc o u n t( 1 0 6/ml) 1.65 ±0.73 .1 ±0.5† 1.9 ±0.32
Macrophages (%) 47.6 ±5.23 3 .6 ±84 8 .9 ±4.5
Neutrophils (%) 30 ±4.52 9 .2 ±4.92 5 .7 ±6.1
Eosinophils (%) 0.7 ±0.25 .7 ±3.6† 1.2 ±0.7
Lymphocytes (%) 1.7 ±1.26 .5 ±2† 2.7 ±1.8
Squamous cells (%) 4.5 ±24 .8 ±1.94 .50 ±1.8
Viability (%) 84 ±48 2 ±68 7 ±5
† signiﬁcant diﬀerences (p<. 05) compared to mild asthmatic patients and healthy controls. Successful sputum induction was achieved in
9/10 severe asthmatics and 8/12 mild asthmatics.
Sputuminductionandprocessing
Before sputum induction all patients inhaled salbutamol
(200μg) via a metered dose inhaler. Baseline FEV1 was mea-
sured and this was repeated following salbutamol and af-
ter each 5-minute inhalation of nebulised hypertonic saline
(3.5%). The procedure was stopped if the FEV1 fell by > 10%
following saline or by > 20% at any time during the induc-
tion procedure. Solid sputum material was separated from
saliva before processing as we have recently reported [14].
Brieﬂy,selectedsputumwasweighedand0.1% DTT(Sigma-
Aldrich, Poole, UK) in phosphate-buﬀered saline (PBS) was
added at a ratio of 4ml to 1g sputum. The sputum was
incubated with DTT at room temperature for 15 minutes
on a rolling mixer. The same volume (4ml to 1g sputum)
of PBS was added to the sputum and then ﬁltered through
48μmnylongauze.Theﬁltratewascentrifugedat400g(Sor-
vall RT6000D, Kendro, Bishop’s Stortford, UK) for 10 min-
utes at 4◦C to pellet cells. The cells were resuspended in
PBS containing 0.1% bovine serum albumin (BSA). The vi-
ability of the sample was determined by trypan blue exclu-
sion staining (Sigma-Aldrich) in a Neubauer hemocytome-
ter (Merck Eurolabs, Lutterworth, UK). Cytospins (Shandon
Scientiﬁc, Sewickley, Pa, USA) of sputum cells that were used
for determination of diﬀerential cell counts were ﬁxed with
methanol and stained with May-Grunwald-Giemsa stain
(Merck-Eurolabs).
Flowcytometricanalysis
Two-colour staining of the sputum cells was performed us-
ing monoclonal antibodies (mAbs) in two combinations:
tube A contained mAbs to CD4 (helper T cell)/CD8 (cy-
totoxic T cell), and tube B contained mAbs to CD3 (pan
T cell)/CD56 (natural killer cell) (all were products of BD
Biosciences). The isotype-matched control mAbs were used.
50μl aliquots of the mononuclear cells from the sputum
cells were added to the polypropylene round-bottom test
tube, and the directly conjugated mAbs (conjugated ﬂu-
orescein isothiocyanate (FITC), phycoerythrin (PE), Cy-
Chrome (Cy), or peridinin chlorophyll-a protein (PerCP))
were added at predetermined optimal dilution. After a 30-
minute incubation, aliquots were washed twice in FACS
buﬀer (phosphate-buﬀered saline/0.2% bovine serum albu-
min). The acquisition was performed using a FACSCalibur
ﬂow cytometer (Becton Dickinson), and analysed using the
CellQuest software program (BD Biosciences). A gate for the
live lymphocyte population was deﬁned by the forward and
side scatter characteristics, and the data was displayed on a
log scale of increasing ﬂuorescence intensity. In addition, the
subtype analysis of CD3+CD56+ cells was done in the spu-
tum of patients with severe asthma and mild asthma. The
subtype analysis was also done to 10 healthy controls for the
comparison. CD3+CD56+ T cells belong to a highly hetero-
geneous subset that includes chronically stimulated conven-
tional CD8+ T cells, T cells, and so called CD1d-restricted
NKT cells, the hallmark of which is the recurrent expression
of Vα24Vβ11 T-cell receptors [15]. For the further detailed
phenotypic analysis of CD3+CD56+ T cells, three- or four-
colour staining, using CD3, CD56, CD25, and additional
markers such as pan TCRγδ mAb, pan TCRβ mAb, CD4,
and CD8 coreceptors and Vα24Vβ11 (all were products of
BD Biosciences) was done.
Statistics
The diﬀerences in the phenotypic characteristics of the
mononuclear cell populations among the patients with se-
vere asthma, mild asthma, and healthy controls were statisti-
cally compared using Anova test. For signiﬁcant Anova val-
ues, the groups were compared by a Tukey’s post hoc test
for the multiple comparisons with an unequal cell size. A
P value <. 05 was considered signiﬁcant. In addition, the
Wilcoxonmatched-pairsigned-ranktestwasusedtodemon-
strate the diﬀerences between the values obtained from the
sputum cells of severe and mild asthmatics.Agnes Hamzaoui et al 3
Table 2: Percentages of lymphocyte subsets and CD4/CD8 ratio in the induced sputum of healthy control, mild asthmatic, and severe
asthmatic patients.
Healthy controls Severe asthmatics Mild asthmatics
CD3+ 91.42 ±8.35 93.12 ±6.11 94.21 ±7.12
CD4+ 65.5 ±18.66 72.65 ±10.22† 68.6 ±9.33
CD8+ 25.6 ±17.21 8 .6 ±9.8† 23.6 ±8.7
CD4+/CD8+ 1.97 ±0.73 .58 ±0.37†† 2.57 ±0.29†
CD19+ 6.33 ±1.82 5.32 ±1.07 4.30 ±0.98
TCR γδ+ 2.63 ±1.72 9.63 ±0.28†† 1.97 ±0.63
CD4+CD25+ 5.25 ±1.45 9.44 ±0.63†† 3.23 ±0.30
† signiﬁcantly diﬀerent from healthy controls. †† signiﬁcantly diﬀerent from healthy controls and mild asthmatic patients.
Table 3: Percentages of subpopulations of NKT (CD3+CD56+) cells and NK (CD3−CD56+) cells in the induced sputum of patients with
severe asthma, mild asthma, and healthy controls.
Healthy controls Severe asthma Mild asthma
CD3+CD56+ 2.14 ±1.72 13.52 ± 4.13†† 2.86 ±1.39
CD4+CD56+ 0.30 ±0.20 0.58 ±0.32 0.29 ±0.07
CD8+CD56+ 2.05 ±0.29 7.43 ±1.05† 2.83 ±1.45
CD3−CD56+ (NK cells) 3.25 ±0.29 5.58 ±4.72 3.83 ±1.45
CD56+αβ TCR 0.93 ±0.18 6.12 ±1.29† 0.92 ±0.87
CD56+γδ TCR 0.97 ±0.25 6.50 ±3.74† 0.89 ±0.45
CD56+Vα24+ Tc e l l s 0 .09 ±0.02 0.82 ±0.07†† 0.07 ±0.05
†† denotes statistically signiﬁcant diﬀerences of the value when compared with that of patients with mild asthma and healthy controls
(P<. 05).
RESULTS
Celltypesininducedsputumofsevereand
mildasthmatics
Subject sputum cell counts characteristics were as sum-
marised in Table 1. Baseline FEV1 expressed as percentage
predicted diﬀered signiﬁcantly between severe asthmatics
and mild asthmatics (P<. 01). There were signiﬁcant dif-
ferences in the total cell count of the sputum cells between
patients with severe asthma compared to patients with mild
asthma and healthy controls (P<. 05). Signiﬁcant diﬀer-
ences were observed in the percentages of eosinophils and
lymphocytes between severe asthmatics and mild asthmatics
(P<. 01).
Thesputumfromtheasthmaticpatientswasanalysedfor
the percentages of B cells (CD19), CD4+, and CD8+ T-cell
subsets among the lymphocytes. The phenotypes of the im-
mune cells showed signiﬁcant diﬀerences between the spu-
tum of severe and mild asthmatic patients (Table 2). A slight
but not signiﬁcant reduction of CD19+ cells was observed
in severe and mild asthmatics comparatively to healthy con-
trols. Decreased percentages of CD8+ T-cells were observed
in severe asthmatic. The percentage of CD4+ cells in the spu-
tum of severe asthmatic patients was elevated resulting in
a higher CD4+/CD8+ T-cell ratio compared to the sputum
of mild asthmatics and healthy controls. There was a pos-
itive correlation between sputum CD4/CD8 ratio and the
sputum percentage of eosinophils in severe asthmatic pa-
tients (r = 0.536, P<. 05). Patients with severe asthma
showed a higher TCRγδ+ cell percentage than mild asthmat-
ics and healthy controls. Severe asthmatic patients expressed
highlevelofCD4+CD25+ cells,whencomparedtomildasth-
matics.
PrevalenceofCD3+CD56+ Tcellsin
severeasthmaticpatients
The proportions of CD3+CD56+ cells in the sputum of pa-
tients with severe asthma were highly expressed when com-
pared to patients with mild asthma and healthy controls
(Table 3). No signiﬁcant diﬀerences were observed in the
CD3−CD56+ cells between mild and severe asthmatics.
The CD3+CD56+/CD3−CD56+ cellular ratio was signif-
icantly increased in severe asthmatics compared to patients
with mild asthma and healthy controls, because of the more
dominance of the NKT cells (P<. 05), (Figure 1).
PhenotypicanalysisofCD3+CD56+ Tcellsin
patientswithsevereasthmatic
The subsets of CD3+CD56+ cells in patients with severe
asthma and mild asthma were analysed in the sputum;
we also analysed these cells in healthy controls (Table 3).
The subsets of CD3+CD56+ cells, especially CD8+CD56+
cells and CD56+ γδ T cells, were signiﬁcantly increased in4 Mediators of Inﬂammation
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Figure 1:RatioofNKT(CD3+CD56+)c ellsandNK(CD3 −CD56+)cellsintheinducedsputumofpatientswithsevereasthma,mildasthma,
and healthy controls.
patients with severe asthmatics compared to healthy con-
trolsandmildasthmatics.Vα24+ TcellsamongCD3+CD56+
cells were signiﬁcantly increased in severe asthmatics. Vα24+
T cells did not show any statistically signiﬁcant diﬀerence
among the mild asthmatic group and healthy controls.
DISCUSSION
This study shows that sputum immune cells in se-
vere asthmatic patients expressed diﬀerent CD3+CD56+,
CD8+CD56+, CD56+ γδ CD56+ Vα24+ T subpopulations,
and NKT/NK cell ratio than patients with mild asthma. The
values of CD8+CD56+ were similar as we have recently re-
ported [14]. No diﬀerences were observed between healthy
controls and mild asthmatics. These ﬁndings may be at-
tributed to the fact that the aetiologies of the severe and mild
asthma were diﬀerent. CD4+ T cells were more predominant
than CD8+ T cells in the sputum of mild and severe asth-
matics. The CD4+ T cells in the sputum of severe asthmatic
patients show increased CD25 expression, comparatively to
mild asthmatics. CD25 characterise both activated cells and
regulatory T cells (Treg), the most speciﬁc marker for Treg
cells is Foxp3, a recently identiﬁed transcription factor gene
that is speciﬁcally expressed in CD4+CD25+ Treg cells. The
sputum eosinophils count was higher in severe asthmatics
compared to mild asthmatics. Our study also conﬁrms that
inducted sputum is a safe method to investigate airway in-
ﬂammation in asthma, as it has been reported by Jatakanon
Ae ta l[ 16].
Severe asthmatics exhibited an increase in CD4/CD8 cell
ratio in comparison with mild asthmatic patients. The sig-
niﬁcantly higher CD4/CD8 ratio conﬁrms the enhancement
ofCD4+ cellsresponseinsevereasthma.IncreasedCD4/CD8
ratioshavebeenalreadysuggestedfromsevereasthmaticspe-
ripheral blood, bronchoalveolar lavage lymphocytes (BAL),
and lung biopsy studies [17, 18]. In the same line of our
report, the recent study of Fabbri et al [19], severe asth-
matics expressed a higher CD4/CD8 T-cell ratio, inﬁltrating
the airway mucosa. On the contrary, Leckie et al [20] failed
to ﬁnd any diﬀerence in the number of sputum CD4+ and
CD8+ cell populations of patients with asthma or healthy
subjects. CD4+ cells of type 2 have also been found in-
creased in blood, biopsies, and BAL of asthmatic patients
[17, 21]. CD4+ cells expressed regulatory cytokines, like IL-
5 that promotes eosinophil diﬀerentiation and activation, as
well as IL-4 and IL-13, which induce IgE production and
eosinophil recruitment via vascular cell adhesion molecule-
1 expression on the vascular endothelium [22]. Increased
eosinophil cells were observed in our severe asthmatic pa-
tients. Eosinophils play a major role in the onset and mainte-
nance of bronchial inﬂammation and tissue injury in asthma
[23,24]. The sputum CD4/CD8 ratio in our severeasthmatic
group correlate to the number of eosinophils, but did not
correlate to IgE levels. Possibly, the higher CD4 cell numbers
observed in our study among severe asthmatics also reﬂect
a persisting release of Th2 cytokines from the above cells,
which both support higher eosinophil levels, despite steroid
treatment. In asthma, Th2 cytokines (IL-13) is elevated in
BAL, bronchial biopsies, and sputum [25], and several cell
types have been described as important sources of IL-13,
including T-lymphocytes [26, 27]. The role of eosinophils in
severe asthmatics is not clear. Wenzel et al [28]h a v ed e m o n -
strated that there are two subtypes of severe asthma, de-
pending on the absence or presence of eosinophils in en-
dobronchial biopsies. Sputum analysis of severe asthmatics
has provided evidence for persistent eosinophilic inﬂamma-
tion[17,19].Similarly,ourasthmaticgrouphadsigniﬁcantly
higher eosinophil percentages. Gibson et al [29]h a v ea l r e a d y
reported heterogeneity regarding sputum eosinophil num-
bers in severe asthmatics.
In this study, CD3+CD56+ cell population was much
higher in the sputum of severe asthmatic patients than pa-
tients with mild asthma and healthy controls. These results
indicate that CD3+CD56+ cells may play a key role only in
the pathogenesis severe asthma. Ohkawa et al [30]s u g g e s t e d
that human CD56+ T cells play an important role in the
Th1 responses. In severe asthmatics, CD3+CD56+-cytokines
production is under studies. Activated T cells with NK cellAgnes Hamzaoui et al 5
markers (NKT cells) in our severe asthmatics may be harm-
ful to the lung. TCRγδ T cells with or without CD56 were
increased in sputum of severe asthmatic patients compared
to mild asthma. TCRγδ cells are predominantly CD4−CD8−
T lymphocytes, appear early in thymic ontogeny, consist 1%
to 10% of the peripheral blood T cells, and are dispersed
in lymphatic and extralymphatic tissues. TCRγδ cells work
as ﬁrst-line defending cells of the innate immune response
and are thought to inﬂuence the nature of the adaptive im-
mune response [31]. T cells expressing NK receptors are be-
lieved to play key roles in patrolling, surveying, and destroy-
ingcellswithanabnormalphenotype [32].Tcellsexpressing
the γδ- r e c e p t o rh a v eb e e nr e p o r t e dt ob ee s s e n t i a lf o rT h 2 -
mediated inﬂammation in patients with acute exacerbation
of asthma [33]. In IL-12 rich microenvironments, CD56 ex-
pression was induced from T cells, which exerted potent cy-
totoxicity [34].
The predominance of CD8+CD56+ cells might be related
to the chronic and massive tissue inﬂammation observed
in severe asthmatics. In certain autoimmune disease, tissue
destruction is dominated by CD8+ T cells in the chronic
stage [35]. The importance of these cells in the development
of branchial inﬂammation in severe asthma is further sup-
ported by the fact that CD8+CD56+ cells is more prominent
in the sputum of severe asthmatics rather than in the sputum
of mild asthmatics. Pittet et al [36] suggested that the CD8+
cytotoxic T lymphocyte (CTL) eﬀector function correlates
betterwithCD56surfaceexpression.Basedonthetightasso-
ciation between cytolytic eﬀectorfunction and CD56 expres-
sion, they proposed that CD56 represents a useful marker to
identify and monitor eﬀector CD8+ T cells in diﬀerent clini-
cal situations. These immune cells with cytolytic eﬀector po-
tential may contribute to the more chronic and destructive
nature that is mediated by CD4+ T cells. Functional study
such as cytotoxic functional assay will be necessary in order
to determine the exact pathogenic role of CD8+CD56+ cells
in severe asthmatics.
Insummary,theCD4+ Tcellswereprominentinthespu-
tum of the patients with severe asthma. Despite decreased
CD8+ T cells observed in severe asthmatics, the number of
CD8+CD56+ cells was the predominant subtype, subscrib-
ing an increase of NKT cells in severe asthmatics than the
other groups. These results suggest that the immunopatho-
genesis of severe asthma is diﬀerent than mild asthma, and
that CD8+CD56+ NKT cells may play an important role in
the immunopathogenesis of severe asthma. The identiﬁca-
tion and analysis of the T lymphocytes from the sputum can
assist in understanding the role of T cells in the pathogenesis
of the diﬀerent groups of asthma. The increased inﬁltration
of the sputum by NK/NKT cells favors recovery? This infor-
mation may help to characterise the pathogenesis of severe
asthma.
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